Publication at Second Faculty of Medicine |
2017
Abstract
Establishment of intravenous immunoglobulin substitution therapy into clinical practice has had important impact on management of primary and secondary humoral immunodeficiencies as well as autoimmune diseases, particularly on those of hematologic or neurologic origin. Further advance in 1990s enabled to introduce subcutaneous immunoglobulin substitution therapy.
Subcutaneous immunoglobulins are comparable in efficacy and safety with intravenous forms. Moreover, they are able to maximally individualize therapy and adapt to patient needs.
Nowadays, SCIG are solely restricted for substitution therapy, however, results of several studies suggest their immunomodulatory potential for treatment of autoimmune diseases.